Previsioni
Il prezzo obiettivo medio degli analisti è 17,32 € (+161,63%). La mediana è 15,49 € (+133,99%).
| Acquista |
23 |
| Mantieni |
6 |
| Vendi |
0 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
BioCryst gains pediatric ORLADEYO approval in Japan, expanding global pediatric franchise
Japan approved once-daily ORLADEYO for hereditary angioedema patients aged 2–12, making it the only oral pediatric prophylactic in that market and strengthening BioCryst's international growth runway. The company has begun US granule shipments and now has ORLADEYO cleared in over 45 countries, while Q2 revenue rose 34% to $218.3 million and cash totaled $354.0 million with positive free cash flow. Management left full-year ORLADEYO guidance unchanged and notes that commercial uptake in Japan depends on the National Health Insurance pricing process; recent revenue growth was also supported by a one-time € licensing payment for navenibart. BioCryst is shifting to an external-licensing R&D model and streamlining operations, which raises execution risk around pipeline assets and international launches. » Altro su finance.yahoo.com
BioCryst turns profitable on Orladeyo and pursues rare-disease acquisitions
BioCryst reported sustained profitability driven by hereditary angioedema drug Orladeyo and expects up to $645 million in sales for 2026, enabling management to fund further rare-disease deals without relying on equity raises. The company has already acquired Astria, adding late-stage candidate navenibart with pivotal data expected in 2027. Financial constraints remain, including negative shareholders' equity and about $822 million in term-loan and royalty obligations, leaving limited room for execution risk if Orladeyo growth slows or acquisitions disappoint. » Altro su finance.yahoo.com
BioCryst receives approval in Japan for HAE drug in young children
The Japanese Ministry of Health has approved ORLADEYO (berotralstat) for prophylactic treatment of hereditary angioedema (HAE) in patients aged 2 to under 12 years. The oral granule formulation showed a consistent safety profile and was generally well tolerated in the APeX-P study of 29 children; the most common treatment-related adverse event was nasopharyngitis. BioCryst will launch the drug in Japan with distribution partner OrphanPacific after completion of pricing and reimbursement processes; approval applications for the same indication are pending with the EMA and Health Canada. » Altro su de.investing.com
BioCryst draws acquisition interest after first profitable year and strong Q2 growth
BioCryst reported its first full year of profitability in 2025 and Q2 2026 revenue rose 33.6% to $218.25 million, supported by Orladeyo which generated $158.2 million in the quarter. The company holds $352.6 million in cash and recently added navenibart via acquisition, with pivotal readout due Q3 2027, sparking takeover speculation. Takeda tops the list of potential strategic buyers given the threat to Takhzyro, followed by AstraZeneca; private equity interest exists but is constrained by BioCryst’s negative shareholders' equity and debt obligations. Analysts remain positive with a consensus target of $20.82 and market attention will focus on navenibart data and any 13D activity. » Altro su finance.yahoo.com
BioCryst Pharmaceuticals raises 2026 revenue guidance, starts pediatric ORLADEYO shipments and ends internal discovery
BioCryst Pharmaceuticals reported Q2 ORLADEYO revenue of $158.2 million, up 10% year over year, and began shipping pediatric oral-pellet prescriptions with 47 scripts by July 31. The company maintained its 2026 ORLADEYO guidance of $625 million to $645 million and raised total 2026 revenue guidance to $690 million to $715 million. BioCryst completed enrollment in the pivotal ALPHA-ORBIT navenibart trial with top-line data expected in Q3 2027, and kept BCX17725 on track for early 2026 data. Management cut 2026 non-GAAP operating-cost guidance to $420 million–$440 million after deciding to end internal drug discovery and close its Birmingham research facility, and reported more than $350 million in cash and investments. » Altro su finance.yahoo.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheNel 2022, BioCryst Pharmaceuticals ha già distribuito 0,19 € di dividendi. L'ultimo pagamento è avvenuto a giugno 2022.
Dati finanziari
Nell'ultimo trimestre, BioCryst Pharmaceuticals ha registrato ricavi pari a 159,17 Mln € e un utile netto di 33,47 Mln €
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 159,17 Mln | 17,19% |
| Utile lordo | 157,78 Mln | 18,03% |
| Utile netto | 33,47 Mln | 204,54% |
| EBITDA | 44,11 Mln | 61,13% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 1,7 Mld € |
Numero di azioni | 257,3 Mln |
Massimo/minimo a 52 settimane | 10,23 € - 5,68 € |
| Dividendi | No |
Beta | 0,54 |
Rapporto P/E | -5,38 |
Rapporto PEG | 0,00 |
Rapporto P/B | -4,67 |
Rapporto P/S | 1,94 |
Profilo aziendale
BioCryst Pharmaceuticals, Inc., una società di biotecnologie, scopre farmaci innovativi, orali e a piccola molecola. La società commercializza peramivir iniettabile, un inibitore della neuraminidasi per via endovenosa per il trattamento dell'influenza acuta non complicata, con i nomi RAPIVAB, RAPIACTA e PERAMIFLU; e ORLADEYO, un inibitore orale della serina proteasi per il trattamento dell'angioedema ereditario. Sta inoltre sviluppando BCX9930, un inibitore orale del fattore D, che è in sperimentazione clinica di Fase II per le malattie mediate dal complemento; BCX9250, un inibitore orale della chinasi 2 simile al recettore dell'activina, che è in sperimentazione clinica di Fase I per il trattamento della fibrodisplasia ossificante progressiva; e Galidesivir, un inibitore della RNA polimerasi RNA-dipendente, che è in sperimentazione clinica di Fase I per il trattamento di vari virus a RNA, tra cui Marburg, febbre gialla, Ebola e Zika. La società ha collaborazioni e accordi di licenza in ingresso con Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; il Dipartimento della Salute e dei Servizi Umani degli Stati Uniti; e The University of Alabama at Birmingham, nonché con Albert Einstein College of Medicine of Yeshiva University e Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. è stata fondata nel 1986 e ha sede a Durham, nella Carolina del Nord.
| Nome | BioCryst Pharmaceuticals |
| CEO | Charles K. Gayer |
| Sede centrale | Durham,
nc Stati Uniti |
| Sito web | |
| Settore | Sanità |
| Industria | Biotecnologia |
| Quotazione in borsa | 04/03/1994 |
| Dipendenti | 435 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | BCRX |
Frankfurt | BO1.F |
Düsseldorf | BO1.DU |
SIX | BO1.SW |
München | BO1.MU |